90222-79-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Amino-5-(methylsulfonyl)benzoic Acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to inhibit certain enzymes, which is crucial in the development of new drugs targeting specific biological pathways.
Used in Agrochemical Production:
In the agrochemical industry, 2-Amino-5-(methylsulfonyl)benzoic Acid is utilized as an intermediate in the production of various agrochemical products, contributing to the development of effective solutions for agricultural challenges.
Used in Medicine:
2-Amino-5-(methylsulfonyl)benzoic Acid is used as a potential therapeutic agent for its anti-inflammatory and anti-cancer properties, offering new avenues for the treatment of various diseases and conditions.
Used in Biotechnology:
In the field of biotechnology, 2-Amino-5-(methylsulfonyl)benzoic Acid is employed for its potential to inhibit the growth of certain microorganisms, which can be instrumental in creating new antimicrobial agents and improving existing ones.
Used in Enzyme Inhibition Research:
2-Amino-5-(methylsulfonyl)benzoic Acid is used as a research tool to study enzyme inhibition, providing insights into the development of drugs that can modulate enzyme activity for therapeutic purposes.

InChI:InChI=1/C8H9NO4S/c1-14(12,13)5-2-3-7(9)6(4-5)8(10)11/h2-4H,9H2,1H3,(H,10,11)

Upstream product

• 26841-51-0 1-amino-2-cyano-4-methylsulphonylbenzene 
• 90610-65-4 methyl 2-amino-5-(methylsulfonyl)benzoate 
• 89938-62-5 2-chloro-5-(methylsulfonyl)benzoic acid 
• 76745-74-9 2-amino-5-(methylsulfanyl)benzoic acid 

Downstream Products

• 1235480-80-4 2-amino-N-(4-sec-butyl-phenyl)-5-methanesulfonyl-benzamide 
• 90610-65-4 methyl 2-amino-5-(methylsulfonyl)benzoate 
• 845616-08-2 2-Iodo-5-methanesulfonyl-benzoic acid 

Relevant academic research and scientific papers

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds.

Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics

The discovery and initial optimization of a novel anthranilic acid derived class of antibacterial agents has been described in a recent series of papers. This paper describes the discovery of 1-acylindazol-3-ols as a novel bioisostere of an anthranilic acid. The synthesis and structure-activity relationships of the indazol bioisosteres are described herein.

Substituted phenyl methanones

The present invention relates to compounds of general formula IA or IB wherein X1 and X2 are each independently N or C—R″ and R1, R2,R3, R4, R5, and R6 are as defined

Heterocyclic-substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.

Substituted acylpiperazine derivatives

The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES

A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

BENZOYL-PIPERAZINE DERIVATIVES

The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.